Search results for "progressive"

showing 10 items of 281 documents

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center bi…

2011

Abstract Background Cetuximab plus irinotecan/folinic acid/5-fluorouracil (5-FU) (IF) was evaluated as first-line treatment of patients with advanced gastric cancer and gastroesophageal junction tumors. Preplanned analyses of the influence of tumor biomarkers on treatment outcome were carried out. Patients and methods Patients received weekly cetuximab (400 mg/m2 on day 1, subsequently 250 mg/m2) plus irinotecan (80 mg/m2) and a 24-hour continuous infusion of folinic acid (200 mg/m2) and 5-FU (1500 mg/m2) on days 1, 8, 15, 22, 29 and 36 of a 50-day cycle, until progressive disease (PD). Results The most common grade 3/4 toxic effects in 49 patients were diarrhea (15%) and skin toxic effects…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.drug_classMedizinLeucovorinPhases of clinical researchCetuximabAntibodies Monoclonal HumanizedIrinotecanAntimetaboliteGastroenterologyFolinic acidStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProgression-free survivalAgedCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanTreatment OutcomeOncologyFluorouracilCamptothecinFemaleFluorouracilbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Early imaging predicts later cognitive impairment in primary progressive multiple sclerosis

2010

Background: Cognitive impairment in primary progressive multiple sclerosis (PPMS) is common and correlates modestly with contemporary lesion burden and brain volume. Using a cohort/case control methodology, we explore the ability of MRI abnormalities, including those in the normal-appearing brain tissue, to predict future cognitive dysfunction in PPMS. Methods: Thirty-one patients recruited into a longitudinal study within 5 years of onset of PPMS were assessed neuropsychologically on average 5.5 years later along with 31 matched healthy controls. MRI data obtained at entry into the study (lesion metrics, brain volumes, magnetization transfer ratio histogram metrics, and magnetic resonance …

AdultMalemedicine.medical_specialtyMagnetic Resonance SpectroscopyTime Factorsprimary progressive multiple sclerosisNeuropsychological TestsAudiologyNerve Fibers MyelinatedLesionWhite matterCentral nervous system diseasemedicineHumansLongitudinal StudiesAgedNerve Fibers UnmyelinatedMultiple sclerosisCognitive disorderBrainCognitionOrgan SizeMiddle AgedMultiple Sclerosis Chronic Progressivemedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureCase-Control StudiesBrain sizeFemaleNeurology (clinical)Verbal memorymedicine.symptomCognition DisordersPsychologyNeuroscienceFollow-Up StudiesNeurology
researchProduct

Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study.

2014

Objective: The objective of this paper is to identify clinical or magnetic resonance imaging (MRI) predictors of long-term clinical progression in a large cohort of multiple sclerosis (MS) patients. Methods: A total of 241 relapsing–remitting (RR) MS patients were included in a nine-year follow-up (FU) study. The reference MRIs were acquired at baseline (BL) as part of a multicenter, cross-sectional, clinical-MRI study. Volumetric MRI metrics were measured by a fully automated, operator-independent, multi-parametric segmentation method. Clinical progression was evaluated as defined by: conversion from RR to secondary progressive (SP) disease course; progression of Expanded Disability Status…

AdultMalemedicine.medical_specialtyMagnetic resonance imaging follow-up multiple sclerosis clinical predictors gray matter atrophypredictormultiple sclerosisDisease courseDisability EvaluationMultiple Sclerosis Relapsing-RemittingInternal medicinefollow-upmedicineHumansSecondary progressiveExpanded Disability Status Scalemedicine.diagnostic_testbusiness.industryMultiple sclerosisDisease progressionFollow up studiesMagnetic resonance imagingclinical predictorsMiddle Agedmedicine.diseaseMagnetic Resonance Imaginggray matter atrophyCross-Sectional StudiesNeurologymultiple sclerosiDisease ProgressionSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessNuclear medicineClinical progressionMRIFollow-Up StudiesMultiple sclerosis (Houndmills, Basingstoke, England)
researchProduct

Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocar…

1994

Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i.v. on days 1, 29; mitomycin C 10 mg/m2 i.v. on day 1. This cycle was repeated every 8 weeks. Out of a total of 34 evaluable patients, 2 (5.8%) had a complete response and 7 (20.6%) had a partial response with an overall median duration of 40 weeks (range 20-128). The median survival of responding patients was not reached after a mean follow-up of 76 weeks, while that of patients with no change and progressive disease was reached at 36 and 13 weeks respectively. Treatment was generally well tolerated with h…

AdultMalemedicine.medical_specialtyMitomycinmedicine.medical_treatmentAdenocarcinomaGastric Adenocarcinoma Chemotherapy Epidoxorubicin Mitomicin CGastroenterologyStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Neoplasm MetastasisAgedEpirubicinAged 80 and overPharmacologyChemotherapybusiness.industryStomachPalliative CareMitomycin CCombination chemotherapyMiddle Agedmedicine.diseaseConfidence intervalSurgeryInfectious Diseasesmedicine.anatomical_structureOncologyFluorouracilAdenocarcinomaFemaleFluorouracilbusinessProgressive diseasemedicine.drug
researchProduct

The differing roles of the frontal cortex in fluency tests

2012

Fluency tasks have been widely used to tap the voluntary generation of responses. The anatomical correlates of fluency tasks and their sensitivity and specificity have been hotly debated. However, investigation of the cognitive processes involved in voluntary generation of responses and whether generation is supported by a common, general process (e.g. fluid intelligence) or specific cognitive processes underpinned by particular frontal regions has rarely been addressed. This study investigates a range of verbal and non-verbal fluency tasks in patients with unselected focal frontal ( n  = 47) and posterior ( n  = 20) lesions. Patients and controls ( n  = 35) matched for education, age and s…

AdultMalemedicine.medical_specialtyNeuropsychological TestsAudiologybehavioral disciplines and activitiesBrain mappingFunctional LateralityFluencyCognitionRaven's Progressive MatricesmedicineHumansSet (psychology)Brain MappingBrain NeoplasmsVerbal BehaviorCognitionOriginal ArticlesMiddle AgedMagnetic Resonance ImagingFrontal LobeCognitive testStrokeFrontal lobeCase-Control StudiesFemaleNeurology (clinical)PsychologyCognitive psychologyGestureBrain
researchProduct

Functional correlates of vertical gaze palsy and other ocular motor deficits in PSP: An FDG-PET study

2014

Abstract Objective To determine the functional correlates of vertical gaze palsy and other ocular motor deficits in patients with progressive supranuclear palsy (PSP) using [ 18 F]fluorodeoxyglucose (FDG-)PET. Methods Twenty-six patients with PSP underwent clinical examination of vertical gaze combined with FDG-PET scans to assess regional cerebral glucose metabolism as a marker of neuronal activity. Of these, eighteen PSP patients were also investigated by electrical nystagmography to determine horizontal ocular motor deficits. Statistical parametric mapping analyses were performed to correlate regional neuronal activity with ocular motor functions. Results In categorical comparisons, pati…

AdultMalemedicine.medical_specialtyNystagmographygenetic structuresSmooth pursuitOcular Motility DisordersLingual gyrusOcular Motility DisordersFluorodeoxyglucose F18OphthalmologymedicineHumansPremovement neuronal activityAgedAged 80 and overPalsyOptokinetic reflexMiddle AgedGazeeye diseasesNeurologyPositron-Emission TomographyFemaleSupranuclear Palsy ProgressiveNeurology (clinical)RadiopharmaceuticalsGeriatrics and GerontologyPsychologyNeuroscienceParkinsonism & Related Disorders
researchProduct

Acute effects of psychological relaxation techniques between two physical tasks.

2016

The concept of recovery strategies includes various ways to achieve a state of well-being, prevent underrecovery syndromes from occurring and re-establish pre-performance states. A systematic application of individualised relaxation techniques is one of those. Following a counterbalanced cross-over design, 27 sport science students (age 25.22 ± 1.08 years; sports participation 8.08 ± 3.92 h/week) were randomly assigned to series of progressive muscle relaxation, systematic breathing, power nap, yoga, and a control condition. Once a week, over the course of five weeks, their repeated sprint ability was tested. Tests (6 sprints of 4 s each with 20 s breaks between them) were executed on a non…

AdultMalemedicine.medical_specialtyRelaxationmedicine.medical_treatmentSports scienceMuscle RelaxationRestPhysical Therapy Sports Therapy and RehabilitationAthletic PerformanceRelaxation TherapyBreathing ExercisesRunning03 medical and health sciencesYoung Adult0302 clinical medicinePhysical medicine and rehabilitationmedicineHumansOrthopedics and Sports MedicineTreadmillMuscle SkeletalProgressive muscle relaxationRelaxation (psychology)Yoga030229 sport sciencesMuscle relaxationMeditationSprintBreathingPhysical therapyExercise TestPhysical EnduranceFemaleRelaxation TherapyPsychologySleephuman activities030217 neurology & neurosurgeryStress PsychologicalPsychophysiologyJournal of sports sciences
researchProduct

Photochemotherapy Alone or Combined with Interferon Alpha-2a in the Treatment of Cutaneous T-Cell Lymphoma

1990

Eighty-two patients with either mycosis fungoides (MF) or parapsoriasis en plaques were treated with psoralens ultraviolet A light (PUVA). Clinical and histologic parameters were followed for a period from 6 months to 10 years. Complete clinical clearing of lesions was observed in 51 patients (62%) and most of them were in limited-plaque MF group or parapsoriasis en plaque. The mean total dose of PUVA for complete clearing was less for early MF. Thirty-one patients (38%) relapsed and responded to additional PUVA. Patients in early stages of the disease remained clear for up to 68 months after the first course of PUVA. Post-treatment skin biopsies with early MF showed histologic clearing. A …

AdultMalemedicine.medical_specialtySkin NeoplasmsCombination therapyConstitutional symptomsDermatologyInterferon alpha-2BiochemistryMycosis FungoidesInterferonmedicineHumansSezary SyndromePUVA TherapyMolecular BiologyDepression (differential diagnoses)AgedNeoplasm StagingMycosis fungoidesParapsoriasisbusiness.industryCutaneous T-cell lymphomaInterferon-alphaCell BiologyMiddle Agedmedicine.diseaseCombined Modality TherapyDermatologyRecombinant ProteinsLymphoma T-Cell CutaneousDrug EvaluationFemalebusinessProgressive diseasemedicine.drugJournal of Investigative Dermatology
researchProduct

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term foll…

2010

Background Allogeneic hematopoietic stem cell transplantation is an effective treatment for patients with poor risk lymphoma, at least in part because of the graft-versus-lymphoma effect. Over the past decade, reduced intensity conditioning regimens have been shown to offer results similar to those of conventional high-dose conditioning regimens but with lower toxicity early after transplantation, especially in patients with chemosensitive disease at transplant. Design and Methods The aim of this study was to analyze the long-term outcome of patients with follicular lymphoma who received an HLA identical sibling allogeneic stem cell transplant with a reduced intensity conditioning regimen w…

AdultMalemedicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentFollicular lymphomaHematopoietic stem cell transplantationGastroenterologyreduced intensity conditioningfollicular lymphomaallogeneic stem cell transplantationInternal medicinemedicinegraft-versus-host diseaseHumansTransplantation HomologousLymphoma FollicularSurvival ratebusiness.industryHistocompatibility TestingSiblingsHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseSurgeryFludarabineSurvival RateTransplantationTreatment OutcomeGraft-versus-host diseaseFemaleOriginal ArticleTransplantation ConditioningbusinessProgressive diseaseFollow-Up Studiesmedicine.drugHLA identical sibling donor
researchProduct